syrs: the income statement

MyFinsight

Syros Pharmaceuticals, Inc. (SYRS)

For the quarter ending 2024-09-30, SYRS made -$19,512K in revenue. -$6,396K in net income. Net profit margin of 32.78%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2024-09-30
Research and development expense, total	20,527
General and administrative expense, total	5,655
Total operating expenses	26,182
Loss from operations	-26,182
Interest income	793
Interest expense	1,312
Fair value adjustment of warrants	-20,305
Net loss applicable to common stockholders	-6,396

Basic eps	-0.16
Diluted eps	-0.16
Basic average shares	39,335,772
Diluted average shares	39,335,772

Unit: Thousand (K) dollars (except for numbers of shares and EPS)